Leap Therapeutics Inc
LPTX2.050USD
0.0000.00%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
84.95MValor de mercado
PerdaP/L TTM
Mais detalhes de Leap Therapeutics Inc Empresa
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Informações de Leap Therapeutics Inc
Código da empresaLPTX
Nome da EmpresaCypherpunk Technologies Inc
Data de listagemJan 24, 2017
CEOOnsi (Douglas E)
Número de funcionários52
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 24
Endereço47 Thorndike Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02142
Telefone16172524343
Sitehttps://www.leaptx.com/
Código da empresaLPTX
Data de listagemJan 24, 2017
CEOOnsi (Douglas E)
Executivos da empresa Leap Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
--
--
Mr. Mark O'Mahony
Mr. Mark O'Mahony
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: seg, 5 de jan
Atualizado em: seg, 5 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
Outro
59.09%
Investidores
Investidores
Proporção
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
Outro
59.09%
Tipos de investidores
Investidores
Proporção
Family Office
14.62%
Corporation
11.53%
Individual Investor
11.07%
Investment Advisor
6.53%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
Outro
48.65%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
109
9.04M
15.96%
-11.00M
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Winklevoss Capital Management, LLC
8.28M
14.62%
+8.28M
--
Oct 24, 2025
Severns (Sean Michael)
6.00M
10.59%
+6.00M
--
Nov 12, 2025
Gilead Sciences Inc
5.32M
9.39%
--
--
Oct 24, 2025
The Vanguard Group, Inc.
1.16M
2.05%
--
--
Sep 30, 2025
BofA Global Research (US)
1.44M
2.55%
+1.44M
+451295.63%
Sep 30, 2025
Acadian Asset Management LLC
1.24M
2.18%
--
--
Sep 30, 2025
Beigene Ltd
1.22M
2.15%
+1.22M
--
Oct 31, 2024
Simplify Asset Management Inc
975.61K
1.72%
+118.25K
+13.79%
Sep 30, 2025
HealthCare Ventures LLC
676.32K
1.19%
-20.91K
-3.00%
Oct 24, 2025
Geode Capital Management, L.L.C.
312.19K
0.55%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
Proporção0.37%
iShares Micro-Cap ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Data
Data ex-dividendo
Tipo
Proporção
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
